Results 81 to 90 of about 50,964 (281)

Antibody profiling of patients with prostate cancer reveals differences in antibody signatures among disease stages

Journal for ImmunoTherapy of Cancer, 2020
Background Previous studies of prostate cancer autoantibodies have largely focused on diagnostic applications. So far, there have been no reports attempting to more comprehensively profile the landscape of prostate cancer-associated antibodies ...
Jin Zhang, Douglas G McNeel, Tun Lee Ng, Hemanth K Potluri, Michael A Newton, Christopher A Maher, Peter S Nelson   +6 more
doaj   +1 more source

Nanomaterials‐mediated glycolysis rewriting to potentiate tumor immunotherapy

BMEMat, EarlyView.
This review systematically summarizes cutting‐edge advances in glycolysis‐rewiring nanomedicines, emphasizing their mechanisms in reversing immunosuppression and reinvigorating antitumor immune responses. Challenges in clinical translation and future directions for designing multifunctional metabolic‐immune modulators are also critically discussed ...
Zilin Ma, Songyan Li, Jie Yan, Xuechun Wang, Wen Zhao, Yunxuan Song, Dongdong Liu, Jianwei Jiao, Xiuying Duan, Guiqiang Zhang   +9 more
wiley   +1 more source

EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1)

, 2017
Recent studies have shown that docetaxel-based chemotherapy confers a survival benefit in patients with castration-resistant prostate cancer (PC). Also epidermal growth factor receptor (EGFR) was found to have multiple roles in prostatic tumorigenesis ...
Hour, Tzyh-Chyuan;Chung, Shiu-Dong;Kang, Wang-Yi;Lin, Ying-Chu;Chuang, Shu-Ju;Huang, A-Mei;Wu, Wen-Jeng;Huang, Shu-Pin;Huang, Chao-Yuan;Pu, Yeong-Shiau, 蒲永孝;黃昭淵   +1 more
core   +1 more source

FAM107A loss facilitates TTK‐OPTN‐mediated mitophagy to drive docetaxel resistance in castration‐resistant prostate cancer

Interdisciplinary Medicine, EarlyView.
In the progression of docetaxel resistance, downregulation of FAM107A releases its transcriptional repression of TTK, leading to TTK upregulation. TTK enhances the interaction and phosphorylation of OPTN. This activates mitophagy in tumor cells, facilitates clearance of damaged mitochondria, reduces intracellular reactive oxygen species accumulation ...
Yishan Zhang, Fan Zou, Mingdong Wang, Chenyue Wu, Yingwei Xie, Yongjun Quan, Wei Yan, Yupeng Zheng, Lianhua Li, Yuexin Liu, Jian Yu, Hao Ping   +11 more
wiley   +1 more source

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer

Frontiers in Oncology, 2019
Most prostate cancers are androgen-sensitive malignancies whose growths depend on the transcriptional activity of the androgen receptor (AR). In the 1940s, Charles Huggins demonstrated that the surgical removal of testes in men can result in a dramatic ...
Qin Feng, Bin He, Bin He
doaj   +1 more source

Chemotherapy options in castration-resistant prostate cancer

Indian Journal of Urology, 2016
The treatment landscape for patients with metastatic castration-resistant prostate cancer (CRPC) is evolving, with recent approvals of immune therapy, novel hormonal therapy, and bone-targeted therapy. Chemotherapy remains an essential component of the armamentarium.
Benjamin A Teply, Ralph J Hauke
openaire   +3 more sources

A compendium of extracellular vesicle biogenesis inhibitors: From bench to bedside

Interdisciplinary Medicine, EarlyView.
This review explores a decade of research on extracellular vesicles (EVs), detailing their biogenesis and roles in health and disease. It emphasizes EVs' relevance for potential medical applications covering various conditions such as cancer, neurodegeneration, inflammation, and infectious diseases, bridging experimental findings with clinical ...
Stefano Vecchione, Ana Talamillo, Juan M. Falcón‐Pérez   +2 more
wiley   +1 more source

In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumours

, 2009
Purpose: Progression to the castration-resistant state is the incurable and lethal end stage of prostate cancer, and there is strong evidence that androgen receptor (AR) still plays a central role in this process.
Snoek, Robert, Gleave, Martin, Fazli, Ladan, Wong, Charmaine, Chan Wong, Erica, Margiotti, Katia, Rennie, Paul, Nelson, Colleen, Cheng, Helen, Wafa, Latif   +9 more
core   +1 more source

The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer [PDF]

, 2006
<b>Purpose</b>: The role of the type I receptor tyrosine kinase (HER) family in progression of prostate cancer is controversial. Breast cancer studies show that these receptors should be investigated as a family.
Traynor, P., Munro, A., Dunne, B., Edwards, J., Bartlett, J.M.S., Pirrett, C.F.   +5 more
core   +1 more source

Reappraisal of glucocorticoids in castrate-resistant prostate cancer

Asian Journal of Andrology, 2014
Recent reports and discussions of preclinical prostate cancer models have emphasized the possibility that enzalutamide resistance may be mediated by glucocorticoid receptors (GR). In both in vitroand xenograft animal studies, it is possible to show that the GR is up-regulated in prostate cancer cell lines and that dexamethasone reverses enzalutamide ...
Oliver Sartor, Christopher C Parker, Johann De Bono   +2 more
openaire   +3 more sources